AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 132 min read$EMBC

Kurdikar Devdatt purchased $141K of EMBC

Kurdikar Devdatt (President and CEO) purchased 30,000 shares of Embecta Corp. (EMBC) at $4.70 ($0.14M total) on 2026-08-12.

Original reporting
SEC EDGAR · Kurdikar Devdatt
Published Aug 13, 2026, 2:50 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 13, 2026, 2:55 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$EMBC
Bullish
medium confidence
Mentioned
$EMBC
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EMBCBullishLow
01

Why it matters

The newest information is the CEO’s open-market purchase details (shares, price, total value) and the post-transaction holdings.

02

Market read

Traders may view the CEO’s purchase as a modest sentiment input, but there is no accompanying operational or financial update.

03

What to watch

The filing states no pre-arranged 10b5-1 plan, but the article does not provide context on prior trading patterns, motivations, or whether the CEO has ongoing planned purchases.

Relevance 5/10Novelty 5/10Timing: filed 2026-08-13, transaction dated 2026-08-12

Background

This is an SEC Form 4 insider transaction disclosure for Embecta Corp., reported by the CEO and President.

Company-level read

Ticker impact

$EMBCBullishMedium confidence
Context

Embecta CEO bought 30,000 shares of EMBC on 2026-08-12 at $4.6979/share, per a new SEC Form 4 filing.

Expected impact

Likely limited near-term impact; any effect should be small and fade unless followed by other disclosures.

Evidence & confidence

The article discloses a fresh Form 4 transaction with size and price, but it does not include new company performance, guidance, or events that would re-rate the stock.

Market effects

Sector

No sector-level implications are provided beyond a single-company insider transaction.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider buys can be driven by diversification, liquidity needs, or routine compensation-related behavior, so the signal may be weaker than it appears.

Key entities

  • issuer
    Embecta Corp.

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Kurdikar Devdatt

    President and CEO who reported the open-market purchase.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

EMBC insider trading history →

Related articles

AUG 17
$EMBCMedAI 8/10

Embecta (EMBC) Q3 2026 Earnings Call Transcript

Embecta (NASDAQ:EMBC) held its FY2026 Q3 earnings call. Revenue was $271.7M, down 8.1% YoY, with U.S. revenue down 24.6% and international up 11.5% on Owen Mumford strength. Adjusted EPS was $0.56. Free cash flow was $41M. FY2026 guidance: revenue $1.015B-$1.035B, adjusted EPS $1.80-$1.90, margin 23.5%-24%.

aol.com10 min
AUG 14
$EMBCHighAI 9/10

Embecta (EMBC) Q3 2026 Earnings Call Transcript

Embecta (EMBC) reported Q3 FY2026 revenue of $271.7 million, down 8.1% YoY, with U.S. revenue down 24.6% and international revenue up 11.5%. Adjusted EPS was $0.56. The company raised FY2026 adjusted operating margin guidance to 23.5% to 24% and EPS to $1.80 to $1.90, reaffirming revenue guidance of $1.015B to $1.035B.

fool.com6 min
AUG 11
$EMBCMed

EMBC Investor Announcement: Embecta Sued on behalf of Investors to Recover Losses after Insulin Pen Issues Lead to 57% Stock Drop

Bleichmar Fonti & Auld LLP said it filed a securities fraud class action against Embecta Corp. (NASDAQ:EMBC) and executives, alleging misleading statements about the strength of its insulin pen needle category. The suit cites a May 5, 2026 stock drop of 57.8% after Q2 results missed guidance, and notes a lead plaintiff deadline of Aug. 17, 2026.

prnewswire.com4 min
AUG 7
$EMBCMed

Embecta Corp. (EMBC): Results of Operations and Financial Condition

Embecta Corp. (EMBC) filed an SEC Form 8-K — Results of Operations and Financial Condition. FOR IMMEDIATE RELEASE Embecta Corp. Reports Third Quarter Fiscal 2026 Financial Results PARSIPPANY, N.J., Aug 7, 2026 (GLOBE NEWSWIRE) – Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three and n

SEC EDGAR 8-K7 min
JUN 30
$EMBCMed

$EMBC Notification: Embecta Accused of Misrepresentations about its Insulin Pen Issues in Securities Fraud Class Action

Bleichmar Fonti & Auld LLP said a securities-fraud class action was filed against Embecta Corp. (NASDAQ:EMBC) and executives, alleging misstatements about the strength of its insulin pen needle category. The suit follows Embecta’s May 5, 2026 stock drop of 57.8% after Q2 results missed guidance; the firm cites a dividend cut from $0.15 to $0.01. Lead plaintiff deadline: Aug. 17, 2026.

prnewswire.com4 min